Debarrment. RPI warrants and represents that it is not debarred under subsection 306 (a) or (b) of the Federal Food, Drug and Cosmetics Act (U.S. Generic Drug Enforcement Act of 1992: 21 USC 335a(a) or (b)) and that to the best of its knowledge and belief it will not use in a capacity the services of any person debarred under such law with respect to services performed under this Agreement and that it will amend certification in light of new information.
Appears in 4 contracts
Samples: Research Collaboration and License Agreement (Ribozyme Pharmaceuticals Inc), Research Collaboration and License Agreement (Ribozyme Pharmaceuticals Inc), Research Collaboration and License Agreement (Ribozyme Pharmaceuticals Inc)
